For years, urolithin A (UA) was a laboratory curiosity: a gut-derived molecule that rejuvenated muscle in aging worms and rodents. The first-in-human trial, published in Nature Metabolism in 2019, asked a simpler question. Is it safe, does it reach the bloodstream, and does it leave a measurable biological footprint in older people? The answers were largely encouraging. They also came with caveats that anyone considering a supplement should understand.
What urolithin A is, and why it's called a postbiotic
Urolithin A is not found in pomegranates themselves. The fruit, along with walnuts and some berries, is rich in ellagitannins and ellagic acid. Certain gut bacteria convert those polyphenols into urolithins, and UA is the most studied. That makes it a postbiotic: a bioactive compound produced by microbial metabolism rather than a live organism or a plant extract.
This matters because the conversion is unreliable. Only a portion of people carry the right microbes to produce meaningful amounts of UA from food. Eating pomegranate juice therefore gives wildly different results from person to person, which is the core rationale for delivering UA directly as an oral compound.
The mitophagy connection
Mitophagy is the cell's quality-control process for mitochondria. Damaged or dysfunctional mitochondria are tagged, engulfed and recycled so healthier ones can replace them. The process becomes less efficient with age, and the buildup of faulty mitochondria is linked to declining muscle strength, endurance and metabolic health.
Preclinical work showed that UA could stimulate mitophagy and improve muscle function in old animals. The human trial set out to see whether anything comparable could be detected in people.
What the trial did
The study was a randomized, placebo-controlled, first-in-human trial in healthy but sedentary older adults. Participants received either a single dose of UA or repeated daily doses for four weeks. Safety was the primary outcome. Secondary outcomes included plasma levels of UA, circulating biomarkers, and gene expression in skeletal muscle biopsies.
The main findings were:
- Safety: UA had a favorable safety profile across the doses tested, with no pattern of serious adverse effects attributed to it.
- Bioavailability: UA appeared in plasma at every dose, so oral delivery works.
- Plasma acylcarnitines: After four weeks at 500 mg and 1,000 mg per day, levels of these fatty-acid-handling metabolites shifted. That is a marker of altered mitochondrial fat metabolism.
- Muscle gene expression: Biopsies showed changes in mitochondrial and cellular-health-related genes, which the authors described as a "molecular signature" of improved mitochondrial function.
The practical dose: 500 to 1,000 mg a day
The doses that moved the biomarkers were 500 mg and 1,000 mg daily for four weeks. These are far above anything a person could reliably get from food, which is one reason the compound is delivered as a purified supplement or ingredient rather than through diet.
The target population in the study was older adults, and they are the group that makes biological sense. Mitochondrial quality control declines with age, and age-related muscle loss is a major driver of frailty and reduced independence. Younger, active people have less obvious room for improvement, although later research has also looked at middle-aged adults.
Mitopure and the commercial context
The study's author affiliation was Amazentis, the Swiss company behind the branded UA ingredient now sold as Mitopure (marketed through Timeline). This is worth noting. The work is legitimate, published and peer reviewed in a respected journal, but it is industry-sponsored, and the product on the shelf is the same compound that was tested. Readers should treat the safety and biomarker data as credible while recognizing the commercial interest in a positive reading.
Subsequent studies have extended the picture. Later randomized trials, some also supported by the company, reported improvements in muscle endurance in middle-aged adults after several months of 1,000 mg daily, and changes in immune cell profiles in older adults. These are promising but are still a young body of evidence.
The limits that matter
The 2019 trial is a starting point, not proof of benefit. The key limitations are:
- Small and short. It was a Phase I-style study with a limited number of participants over four weeks. Long-term safety and durability of effects are not established.
- Biomarkers, not outcomes. The study showed molecular changes, not that participants walked farther, grew stronger or lived healthier. Gene expression and acylcarnitine shifts suggest mitochondrial effects but do not guarantee clinical benefit.
- Mitophagy was inferred, not directly watched. The authors report a signature consistent with improved mitochondrial health. Directly measuring mitophagy flux in living human muscle is technically very difficult.
- Narrow population. Participants were healthy and sedentary. Results may not carry over to people with chronic disease, those on multiple medications, or very frail patients.
- Not a drug. UA is sold as a supplement or food ingredient, not an approved therapy for sarcopenia or any condition. Anyone with a medical condition or on medication should talk to a clinician first.
Why this matters for oral delivery science
From a delivery standpoint, the study shows that a microbiome-derived metabolite can be bypassed. Instead of relying on variable gut conversion, giving the end product directly produces consistent plasma levels. That logic could extend to other postbiotics whose benefits are currently locked behind individual microbiome differences.
The bottom line
The trial shows that urolithin A, at 500 to 1,000 mg per day, is well tolerated and bioavailable in older adults, and that it nudges muscle and blood markers in the direction of better mitochondrial health. It does not yet show that taking it will make you stronger or live longer. For older adults curious about the compound, the evidence supports cautious interest, ideally alongside exercise, adequate protein and medical guidance, rather than treating a pomegranate-derived pill as a shortcut.
